Supercharged immune cells take aim at deadly childhood brain cancers
NCT ID NCT04099797
Summary
This early-stage trial is testing a new type of cell therapy for aggressive brain tumors that have returned or stopped responding to standard treatments. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to better recognize and attack cancer cells, and then infuse them back into the patient. The main goal is to find the safest dose and method of delivering these modified cells, which are given both into a vein and directly into the fluid around the brain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.